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Abstract
Background: In Belgium, different routine surveillance systems are in place to follow-up Lyme borreliosis trends.
However, accurate data on the disease and monetary burden for the different clinical manifestations are lacking.
Despite recommended antibiotic treatment, a proportion of Lyme patients report persisting aspecific symptoms for
six months or more (e.g. fatigue, widespread musculoskeletal pain, cognitive difficulties), a syndrome now named
“post-treatment Lyme disease syndrome” (PTLDS). Controversy exists on the cause, incidence and severity of PTLDS.
This study aims to estimate the incidence of PTLDS in patients with Lyme borreliosis and to quantify the disease
burden and economic costs associated with the different clinical manifestations of Lyme borreliosis in Belgium.
Methods: The project is a prospective cohort study in which about 600 patients with an erythema migrans and 100
patients with disseminated Lyme borreliosis will be followed up. Questionnaires, including the SF-36 vitality and pain
subscale, the Cognitive Failure Questionnaire and the EQ-5D-5L, will be used to collect information on acute and
persisting symptoms and the impact on quality of life. Symptom frequency and severity will be compared with
self-reported pre-Lyme health status, a control group and existing Belgian population norms. Additionally, information
on the associated costs and possible risk factors for the development of PTLDS will be collected.
Discussion: A study of the health burden will allow evaluation of the relative importance of Lyme borreliosis in Belgium
and information on the economic cost will help to formulate cost-effective measures. There are only few prospective
studies conducted estimating the incidence of PTLDS and even though discussion exists about the prevalence of
subjective symptoms in the general population, a control group of non-Lyme borreliosis participants has often not been
included.
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Background
Lyme borreliosis is a multisystem infectious disease
caused by bacteria from the Borrelia burgdorferi sensu
lato complex. These spirochetes are transmitted by hard
ticks, predominantly by Ixodes ricinus in Europe. Lyme
borreliosis is the most prevalent arthropod-borne disease
in Europe and North America [1, 2]. Asymptomatic in-
fections are frequent [3–5]. If disease develops, it can
cause a wide range of symptoms. The most common
clinical manifestation is an erythema migrans (EM), a
red expanding rash which occurs in 60 to 95% of symp-
tomatic infections, within days to weeks after the tick
bite [6–11]. In this early disease stage, flu-like symptoms
(e.g. fever, headache, fatigue, arthralgia’s, myalgia’s) may
accompany EM or appear separately. If an infection is
not treated with appropriate antibiotics, it can possibly
evolve to disseminated Lyme borreliosis (weeks, months
or years after the tick bite) affecting the skin, the ner-
vous system (Lyme neuroborreliosis), the joints (arth-
ritis) or more rarely, the heart or the eyes [1, 12].
Despite adequate antibiotic treatment, it has been re-
ported that some people still suffer from a range of non-
specific symptoms after an infection: fatigue, widespread
musculoskeletal pain or cognitive difficulties (e.g. mem-
ory problems, difficulties concentrating, problems find-
ing words). If these symptoms persist for more than six
months after treatment in correctly diagnosed Lyme
patients and are of such severity that they influence the
patient’s daily life, this is referred to as post-Lyme dis-
ease syndrome [2], later named post-treatment Lyme
disease syndrome (PTLDS) [13–15].
The frequency of subjective symptoms after treat-
ment for Lyme borreliosis reported in the literature
varies widely; for early Lyme borreliosis (EM) it ranges
between 5 and 20% [1, 13, 16–19] reaching 36% if
included patients present systematic symptoms as well
(e.g. flu-like symptoms) [14]. A review by Koedel et al.
(2015) reported that PTLDS symptoms developed in 5–
54% of Lyme patients that suffered from Lyme neuro-
borreliosis [16]. There is controversy and concern
about the prevalence of these aspecific symptoms in the
general population and although it is advised, only few
studies included a non-Lyme borreliosis control group
[17, 19–22]. The pathogenesis of the syndrome is still
unclear, different possible explanations have been
suggested (e.g. persistent infection, post-infective fa-
tigue syndrome, natural response after treatment, auto-
immune mechanisms, intercurrent conditions) but no
conclusions can be made [15, 17, 23]. Several risk
factors for the development of PTLDS have been hy-
pothesized, including dissemination of disease, delayed
diagnosis and treatment, more severe symptoms at
diagnosis and the elevation of immune mediators (e.g.
elevated CCL19) [15, 23–25].
It is thought that co-infections with other tick-borne
pathogens such as Anaplasma spp. and Babesia spp. can
exacerbate the clinical presentation of Lyme borreliosis:
they can increase the severity of initial Lyme symptoms,
causing unexplained leukopenia, thrombocytopenia or
anemia, or high-grade fever after treatment [2, 26]. In
the last years, other less known tick-borne pathogens
have been found to circulate in Belgian ticks, amongst
others, Borrelia miyamotoi, Neoehrlichia mikurensis and
Rickettsia spp. [27–29]. It is unclear to what extent co-
infections with these and other tick-borne pathogens
may affect persisting symptoms after treatment of Lyme
borreliosis [2, 30–35].
In Belgium, it is estimated that, every year, approxi-
mately 10.000 people consult a general practitioner (GP)
with an erythema migrans and 200–300 people are hos-
pitalized due to disseminated Lyme borreliosis [36, 37].
Although, up to now, no increasing trend in the Lyme
borreliosis incidence has been observed (based on the
long-term surveillance systems in place), the disease is
assumed to represent a significant health and cost bur-
den for the population and the health system in Belgium.
This has however not yet been assessed. Lyme borrelio-
sis and especially its possible long-lasting symptoms,
even after treatment, remain a subject of controversy in
Belgium, as in other parts of the world [2, 38]. In order
to provide some answers to this debate, this prospective
study is set up.
Study objectives
The aim of the study is to evaluate the incidence of and
possible risk factors for the development of post - treat-
ment Lyme disease syndrome (PTLDS) and to estimate
the disease burden and economic cost associated with




The core of HUMTICK is a prospective cohort study
with follow-up of patients with Lyme borreliosis and a
non-Lyme borreliosis control group (in a 1:1 ratio).
Questionnaires will be used to collect information on
duration and severity of symptoms, health related quality
of life, costs and possible risk factors for the develop-
ment of PTLDS. At the end of the follow-up, a case-
control study will be set up within a sub-cohort of EM
patients, to analyze tick-borne co-infections as a possible
risk factor for the development of PTLDS. In this case-
control study, cases are defined as EM patients with
PTLDS and controls (in a 1:2 ratio) as patients in which
EM resolves without persisting symptoms. To search for
the presence of these other tick-borne diseases a blood
sample will be collected from all the patients in the EM
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sub-cohort at the moment of their diagnosis (acute in-
fection). In addition to the prospective study, existing
databases will be consulted to obtain supplementary
data, necessary for the calculation of the full disease and
cost burden of the different clinical manifestations of
Lyme borreliosis.
Study population
Two sub-cohorts will be enrolled in the cohort study;
one cohort consisting of patients who consult a GP with
an erythema migrans and a second consisting of patients
with confirmed disseminated Lyme borreliosis (e.g. neu-
roborreliosis, Lyme arthritis, Lyme carditis) diagnosed
by a specialist physician in a hospital. A non-Lyme bor-
reliosis control group, matched for age and gender is
added (in a 1:1 ratio) to allow comparison between the
cohorts and the general population. Children (<18 years)
and pregnant women will be excluded from the study.
All participants will sign an informed consent form prior
to inclusion. The case definitions for inclusion for co-
hort 1 and 2 are shown in Table 1.
Participant enrollment
Participants are enrolled since June 2016 and up to
August 2018 with follow-up ending no later than
February 2019. For cohort 1 (EM), a network of approxi-
mately 200 GPs is currently being set up in areas in
Belgium that are highly endemic for tick bites and Lyme
borreliosis. All patients complying with the case defin-
ition are invited to participate, until inclusion of a suffi-
cient sample. Patients with confirmed disseminated
Lyme borreliosis (cohort 2) are enrolled through the
hospitals linked to the Belgian National Reference Cen-
ters (NRC) for Lyme borreliosis: Cliniques Universitaires
Saint-Luc-UCL and UZ Leuven (infectious diseases,
neurology and rheumatology departments). If this is not
sufficient to attain the desired sample size, other hospi-
tals will be involved at a later stage (2017–2018). Partici-
pants of the non-Lyme borreliosis control group are
selected by the patients in cohorts 1 and 2, among per-
sons in their own environment with the same gender,
comparable age (+/− 5 years) and no prior Lyme borre-
liosis diagnosis. The participants are included in the
study after validation of the criteria.
Sample size estimates and power calculation
For the sample size calculation of cohort 1, we assume
that 12.5% of EM patients will develop PTLDS (mean of
5–20% [1, 13, 16–19]) in comparison with 5% [19] of the
non-Lyme controls developing the same symptoms. For
the sample size calculation of cohort 2, we assume 20%
of disseminated Lyme patients developing PTLDS. With
an alpha of 0.05, a power of 90 and a cohort-controls ra-
tio of 1:1, this means that we need 285 EM patients in
cohort 1 and 93 disseminated Lyme patients in cohort 2
(2 sided-test) to allow detection of a risk ratio (RR) of re-
spectively 2.5 and 4.
However, to analyze the association between PTLDS
and co-infections as a risk factor in the case-control
study (set-up within cohort 1), we need 74 cases of
PTLDS and 148 controls based on an alpha of 0.05, a
power of 0.80, a case-controls ratio of 1:2 and the
assumption of a less than medium effect size of 0.4
(2-sided test). This means that, if 12.5% of the EM
patients develop PTLDS, we need to extend cohort 1
to 592 EM patients in order to have 74 cases in the
case-control study. Taking into account a reasonable
loss to follow-up (± 25% over 2 years), 780 EM pa-
tients and 120 disseminated Lyme patients need to be
included in the study.
Data collection procedures
Data collection will start when the patient is diagnosed
(T0) with Lyme borreliosis at the consultation with the
GP (cohort 1) or in the hospital (cohort 2). During this
consultation, the first part of the first paper question-
naire is filled in together with the treating physician
(questions on comorbidity, acute symptoms, diagnosis
and treatment). The second part of the questionnaire
can be filled in by the patients themselves after the con-
sultation (questions on socio-demographic parameters,
general health before Lyme borreliosis, tick bite expos-
ure, acute symptoms and costs). The patients’ follow-up
questionnaires are completed online (or on paper if pre-
ferred by the patient) at different points in time: after
1 month, 3 months, 6 months, 12 months and
24 months. The period of patient follow-up depends on
the moment of enrollment and will last maximum
24 months (patients enrolled in early study phase) and
minimum 6 months (patients enrolled in final phase of
Table 1 Case definitions for inclusion in the HUMTICK study (2016)
Case definition
Cohort 1: EM - Clinical presentation of EM, confirmed by a GP
Cohort 2: Confirmed disseminated
Lyme borreliosis
- Positive polymerase chain reaction (PCR) or culture
OR
- Positive serology AND at least one clinical manifestation compatible with disseminated Lyme borreliosis
(confirmed by the treating physician) [12]
[see Additional file 1 for the specific description of this case definition]
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enrollment). Control persons will be requested to fill in
a questionnaire at inclusion, after six months and after
one year. The blood sample for the patients of cohort 1
(EM) will be collected at T0.
Post-treatment Lyme disease syndrome (PTLDS)
PTLDS is defined (in line with the case definition for
post-Lyme disease syndrome proposed by the Infectious
Diseases Society of America (IDSA) [2, 13]) as the new
onset of fatigue, widespread musculoskeletal pain and/or
cognitive difficulties in patients diagnosed with and
treated for Lyme borreliosis. Symptoms should occur
within six months after the diagnosis, be present for more
than six months (continuous or relapsing) and impact the
patient’s daily life functioning (quality of life). Patients will
be excluded if the symptoms are not new or when there is
another explanatory cause for their symptoms.
To apply this case definition, the first patient question-
naire (T0) will assess the presence and severity of the
subjective symptoms, as well as the impact on the pa-
tient’s life, before the onset of their Lyme borreliosis
(during their “pre-Lyme” general health status). The
post-treatment presence, severity and impact of the sub-
jective symptoms will be assessed in the same way, in
the different follow-up questionnaires (from 3 months
onwards). This will allow comparison between the pre-
and post-Lyme health status of the patient.
In order to assess the severity and impact more accur-
ately, validated questionnaires will be used:
 The SF-36 is a self-report 36-item health survey
(8 subscales) which has been used widely and was
shown to have good reliability and validity [39–41].
In our study two subscales are used; the SF-36
vitality subscale (4 items) to assess fatigue and the
SF-36 bodily pain subscale (2 items) to assess
widespread musculoskeletal pain.
 The Cognitive Failure Questionnaire (CFQ), a 25-item
questionnaire of which psychometric properties have
been proven to be good, is used to evaluate cognitive
difficulties [42, 43].
 The EQ-5D-5L, a standardized non-disease specific in-
strument to evaluate the health-related quality of life,
developed by the EuroQol group association [44–46],
is added to each questionnaire to assess the impact of
the symptoms on the patient’s quality of life.
 The Global Activity Limitation Index (GALI), a
single item instrument, is added to the questionnaires
from 6 months onwards since it measures the
presence of long-lasting (≥ 6 months) health related
activity limitations [47–49].
The same questionnaires will be used for people from
the non-Lyme borreliosis control group, to allow analysis
of the incidence of the same symptoms in the general
population. Furthermore, currently Belgian population
norms exist for the SF-36 vitality, SF-36 bodily pain, the
EQ-5D-5L and the GALI, CFQ norms are only available
for the Dutch population [50–54].
Finally, the GPs of the patients in cohort 1 (EM) will
fill in an online follow-up questionnaire, based on the
patient’s medical file, after six and twelve months. Ques-
tions are asked about possible supplementary consulta-
tions, additional diagnoses, new treatments prescribed
and laboratory results if requested. This will allow com-
parison between the patient’s and GP’s perspectives on
the subjective symptoms.
Risk factors for PTLDS
To identify possible risk factors for the development of
PTLDS, information on comorbidity, tick bite exposure,
severity and duration of symptoms presented, prescribed
treatment (type, duration) as well as socio-demographic
variables (age, sex, education and employment status)
will be collected during the complete study. The blood
samples collected at T0 from EM patients will be tested,
by means of a multiplex PCR, for the presence of Ana-
plasma spp., Rickettsia spp., Neoehrlichia mikurensis,
Borrelia miyamotoi and Babesia spp. at the Laboratory
for Zoonosis and Environmental Microbiology (RIVM),
the Netherlands [55].
Disease burden
The Burden of disease will be expressed in Disability-
Adjusted Life Years (DALYs), a summary health measure
comprising both mortality and morbidity. DALYs meas-
ure the healthy life years lost due to illness and equal
the sum of the years lived with disability (YLDs) and the
years of life lost due to premature mortality (YLLs). The
YLDs are calculated based on the occurrence, severity
(disability weights (DW)) and duration of the disease
health states [56–58]. An incidence approach will be
used for the occurrence of the different clinical manifes-
tations of Lyme borreliosis, where the incidences of EM
and disseminated Lyme will be estimated based on exist-
ing literature and surveillance systems currently in place
in Belgium (e.g. sentinel network of general practi-
tioners, network of sentinel laboratories and minimal
clinical data) [36, 37]. The cohort study will provide an
estimate of the incidence of PTLDS, of the symptom du-
rations for the different clinical manifestations as well as
estimates of the group specific disability weights. The
latter will be derived from the participants’ EQ-5D-5L
responses: following the EQ-5D-5L user guide the EQ-
5D-5L scores will first be converted into utilities using a
pre-existing preference valuation set for EQ-5D health
states of the Belgian (Flemish) adult population [59–61].
The resulting utility, a value between 0 (death) and 1
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(full health), will then be transformed to DWs by sub-
tracting it from the EQ-5D population averages for the
same sex and age-group [52, 62, 63]. Since Lyme related
mortality is exceptional and no Lyme related deaths have
been reported in Belgium between 1998 and 2014 (only
data available), YLLs will equal zero.
Costs
To minimize recall bias between two consecutive ques-
tionnaires (recall periods up to 12 months at the end of
the follow-up period), patients are invited to keep a cost
diary during the complete study period. The patients’
questionnaires assess direct and indirect non-medical
costs (e.g. travel costs, absence from work, paid help)
and provide information on direct medical costs related
to medication use, consultations and hospitalizations
(e.g. how many visits to a GP/specialist/…, use of over
the counter medication). Additional details on some of
these direct medical costs, which can’t be provided by
the patients themselves, are collected through the
follow-up questionnaires completed by the GPs (e.g. in-
formation on the laboratory tests). The standard unit
costs (the price of medication, a consultation, a labora-
tory test, a hospitalization) will be obtained from official
sources (e.g. Belgian centre for pharmacotherapeutic in-
formation (BCFI), National Institute for Health and Dis-
ability Insurance (RIZIV)). Supplementary data on
hospitalization costs will be collected through the min-
imal hospital data (MZG), minimal financial data (MFG)
and Belgian health insurance databases.
Statistical analysis
All analyses will be performed in R [64]. A conditional
log-binomial regression model with adjustment for co-
morbid illness will be used to compare the development
of the non-specific disease symptoms between the differ-
ent cohorts and the “matched” non-Lyme borreliosis
control group in order to calculate the incidence of
PTLDS in patients with Lyme borreliosis [65]. Within
cohort 1 & 2, a multivariate log-binomial regression
model will be used to calculate exposure risk ratio (RR)
of the risk factors for development of PTLDS. For the
case-control, the odds ratio (OR) determination for tick-
borne co-infections as a risk factor will be done using a
multivariate logistic regression. The multivariate models
will include adjustment for potential confounding vari-
ables (age, gender and comorbid illness).
The burden of disease will be estimated in collabor-
ation with the “Institut de recherche santé et société
(IRSS) Université catholique de Louvain (UCL)” using
the DALY package [56–58, 66]. The total costs (mean,
median & confidence intervals) for each of the different
clinical manifestations, including PTLDS, will be calcu-
lated by combining the different data sources. The cost
analysis will be carried out in collaboration with the
Centre for Health Economics Research & Modeling Infec-
tious Diseases (CHERMID), University of Antwerp (UA).
Discussion
Lyme borreliosis has been an increasingly “hot topic” in
Belgium and the rest of the world, with uncertainties
and intensive debates on the burden of the disease and
on possible long-lasting (“chronic”) symptoms.
The incidence of PTLDS has been estimated in previ-
ous studies, but the reported results vary widely. This is
likely related to differences in the inclusion criteria and
PTLDS case definitions used, as well as to the variation
among study designs [15]. The strength of the presented
study lies in the combination of different methodologies
which aim at collecting objective data with regard to
PTLDS: the prospective study design allows collecting
detailed information throughout the complete disease
progression and minimizes recall bias; the inclusion of a
non-Lyme borreliosis control group allows controlling
for the background prevalence of aspecific symptoms in
the general population; through the use of validated
questionnaires the severity of the aspecific symptoms
will be assessed (and afterwards compared) accurately.
The availability of Belgian population norms for some of
the validated questionnaires is an additional benefit. Fur-
thermore, the use of parallel questionnaires for the pa-
tients and their GPs allows comparison between the
different perspectives on the persistent aspecific symp-
toms as well as to obtain detailed information on pos-
sible risk factors (e.g. comorbidity, diagnosis, treatment,
complications). By looking at both the prevalence and
the severity of the symptoms occurring with PTLDS, as
well as the impact on the patient’s life, we will be able to
assess all components of the PTLDS case definition [13].
Different possible risk factors will be assessed through
the patient questionnaires and the analyses of other tick-
borne co-infections (in EM patient blood samples) al-
lows collection of innovative data on the importance of
co-infections on the clinical presentation and progres-
sion of Lyme borreliosis. A better comprehension of this
syndrome and its risk factors will allow informing health
care providers and patients about what to expect after
treatment and, if possible, to early identify those patients
at increased risk.
The estimation of the burden of disease, quantified by
a composite health measure, can be used to compare
and prioritize between the different clinical manifesta-
tions of Lyme borreliosis but also between different dis-
eases and health interventions, in order to set public
health priorities [67]. Some European projects assessed
the burden of different communicable diseases but they
did not include Lyme borreliosis [67, 68]. A study in the
Netherlands did estimate the disease burden for Lyme
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borreliosis and found that the majority of the substantial
burden is caused by persisting symptoms [69]. The add-
itional benefit of our study for the burden estimation is
again its prospective study design. In the end, the results
will be used to inform the general public, patients asso-
ciations, policymakers and health care providers on the
actual disease burden related to the different stadia of
Lyme borreliosis in Belgium.
A few European studies have examined the costs asso-
ciated with Lyme borreliosis but often only part of the
costs were included (e.g. costs of Lyme neuroborreliosis
in Sweden [70], cost of testing [71] and of hospital care
in Germany [72]). One study in Scotland included both
direct and indirect costs for early and late Lyme borre-
liosis patients and follow-up costs [73]. These studies
didn’t include the specific supplementary cost for pa-
tients with PTLDS although it is expected to contribute
significantly to the overall costs of Lyme borreliosis. A
recent American study showed that PTLDS-related diag-
noses are associated with notably higher costs and health
care utilization ($ 3798 higher costs and 66% more out-
patient visits) as compared to Lyme borreliosis without
PTLDS-related diagnoses [21, 74]. Through the inclusion
of different costs (both direct and indirect, medical and
non-medical) for both the patients and the health care
system, this study will provide an overall view of the costs
associated with Lyme borreliosis, its diagnosis, treatment,
follow-up, etc.. The results could be used in future cost-
effectiveness analyses of potential interventions.
A first possible limitation of the study is the work–
load for the patients at the moment of inclusion (long
questionnaire) which might keep them from participat-
ing. However, in the context of the current attention for
Lyme borreliosis in the media and the debate on existing
persisting symptoms, we believe we will find sufficient
patients willing to participate to the study. Secondly, as
prescribed in the Belgian guidelines for the diagnosis
and treatment of Lyme borreliosis, diagnosis of an EM is
solely based on clinical symptoms. This implies that the
inclusion of EM patients in our study is dependent on
correct EM recognition by the participating GPs. As a
reminder, the clinical signs of an EM, possible differen-
tial diagnoses and corresponding pictures are provided
to the participating GPs at the start of the study. The
diagnosis of disseminated Lyme borreliosis is based on
both clinical symptoms recognized by specialists and
laboratory testing. Third, due to project time restric-
tions, we will only be able to follow up patients during a
maximum of two years. It would have been interesting
to follow up patients for a longer period. Many patients
and patient associations indeed have questions about
symptoms after a longer period after treatment. How-
ever a longer study period is likely to induce an import-
ant loss to follow-up over time. Finally, the study will
not allow the collection of data with regard to a group
of patients who attribute their persisting aspecific symp-
toms (fatigue, musculoskeletal pains and cognitive disor-
ders) to Lyme borreliosis, but without having a
confirmed diagnosis.
In conclusion, through its multidisciplinary approach,
the HUMTICK prospective cohort study allows address-
ing multiple relevant research questions with regard to
Lyme borreliosis; the enrollment of both EM patients
(early localized Lyme) and disseminated Lyme borreliosis
patients, together with the follow-up over time, will not
only allow to estimate the incidence of PTLDS but also
to estimate the disease burden and cost associated with
the different manifestations of Lyme borreliosis, specific-
ally in Belgium. In addition, the study design allows sim-
ultaneous evaluation of risk factors for the development
of PTLDS and will so improve the understanding of the
evolution of the different clinical manifestations of Lyme
borreliosis after treatment.
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